A comprehensive view of AptarGroup Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Aptar Pharma acquires worldwide license for Orbital Dry Powder Inhaler from Pharmaxis for undisclosed amount; high payload Orbital technology delivers up to 400 mg of powders in divided doses without the need to reload

Wells Fargo reiterates Aptar at overweight with US$125 target, noting pharma segment's Q2 strong growth should continue given solid fundamentals; Beauty + Home approaching pre-pandemic levels, but weakening consumer may thwart progress in fragrance/beauty

Aptargroup Q2 2022 Review Presentation

Aptar CEO Stephan Tanda returns to CNBC’s ‘The Exchange’ to discuss current tight labor market in US, noting Aptar pays competitive wages, brings in skilled labor with temporary work visas, and is partnering with refugee organization Tent.org

Aptar’s Q2 net income up 15.1% year-over-year to US$63.6M amid lower restructuring costs, lower net investment losses, a US$2M miscellaneous expense in year-ago period; net sales up 4.1% to US$844.5M on improved volume, increased pricing in each segment

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count